List of Regenerative Medicine Companies in Washington - 6

DMXi makes oral care products based on peptides derived from the Amelogenin protein. Their products are designed to strenghen, desensitize, and brighten teeth.

Oisin Biotechnologies is a longevity therapeutics platform company focused on creating genetic medicines to combat a variety of age related diseases. When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function. Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases. Oisín Biotechnologies is developing a highly precise, DNA-targeted intervention to clear these cells. As a recent study has shown, clearing senescent cells both reduces negative effects of aging pathologies and also extends median lifespan and survival.

Ora Biomedical, Inc. is a new pharmaceutical company in the longevity biotechnology sector that identifies and characterizes healthy aging therapeutics for further clinical and commercial development. Ora Biomedical separates itself from other longevity biotech companies by building in large-scale drug discovery and validation at the core of our scientific operations. With robust preclinical discovery at the heart of our approach, we identify novel aging targets and new interventions for known targets. Most importantly, we will leverage large-scale operations to perform drug studies that combine known and novel healthy aging interventions to identify those that produce breakthrough increases in healthy lifespan and/or mitigate disease-mediated pathology.

Cell models for human disease.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Seattle Children's is a pediatric healthcare provider offering a wide range of healthcare services for children.